JPH05507065A - 抗ウイルス性組成物及びその使用方法 - Google Patents
抗ウイルス性組成物及びその使用方法Info
- Publication number
- JPH05507065A JPH05507065A JP91507617A JP50761791A JPH05507065A JP H05507065 A JPH05507065 A JP H05507065A JP 91507617 A JP91507617 A JP 91507617A JP 50761791 A JP50761791 A JP 50761791A JP H05507065 A JPH05507065 A JP H05507065A
- Authority
- JP
- Japan
- Prior art keywords
- group
- composition
- compound
- composition according
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 238000000034 method Methods 0.000 title claims abstract description 17
- 230000000840 anti-viral effect Effects 0.000 title claims description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 54
- 239000003446 ligand Substances 0.000 claims abstract description 36
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 16
- 239000001257 hydrogen Substances 0.000 claims abstract description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 15
- 239000003443 antiviral agent Substances 0.000 claims abstract description 8
- 150000004820 halides Chemical class 0.000 claims abstract description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 150000004703 alkoxides Chemical group 0.000 claims abstract description 3
- 201000010099 disease Diseases 0.000 claims description 87
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 87
- 238000011282 treatment Methods 0.000 claims description 71
- 241000700605 Viruses Species 0.000 claims description 44
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 21
- 229940079593 drug Drugs 0.000 claims description 18
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims description 12
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 11
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 9
- 230000006872 improvement Effects 0.000 claims description 8
- 125000004429 atom Chemical group 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 241000701161 unidentified adenovirus Species 0.000 claims description 7
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 4
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 4
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical class [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 claims description 4
- 229910001882 dioxygen Inorganic materials 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 150000001450 anions Chemical class 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims 10
- 241001529453 unidentified herpesvirus Species 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 5
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 description 45
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 41
- 229940125833 compound 23 Drugs 0.000 description 41
- 238000011081 inoculation Methods 0.000 description 29
- 239000000758 substrate Substances 0.000 description 26
- 238000012809 post-inoculation Methods 0.000 description 25
- 238000002255 vaccination Methods 0.000 description 20
- 239000013553 cell monolayer Substances 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 11
- 210000003683 corneal stroma Anatomy 0.000 description 10
- 238000011161 development Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 206010023332 keratitis Diseases 0.000 description 9
- 239000011159 matrix material Substances 0.000 description 9
- 208000030533 eye disease Diseases 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 230000009385 viral infection Effects 0.000 description 7
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 6
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 208000036142 Viral infection Diseases 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 206010051559 Corneal defect Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 238000004776 molecular orbital Methods 0.000 description 4
- -1 organometallic cobalt compounds Chemical class 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 210000003501 vero cell Anatomy 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 2
- 241000257465 Echinoidea Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010037508 Punctate keratitis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010066901 Treatment failure Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 2
- 229960003962 trifluridine Drugs 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 206010016818 Fluorosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- WCIDIJQCEUODDY-UHFFFAOYSA-N chloro(dimethyl)sulfanium Chemical compound C[S+](C)Cl WCIDIJQCEUODDY-UHFFFAOYSA-N 0.000 description 1
- 208000037516 chromosome inversion disease Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- IVMYJDGYRUAWML-UHFFFAOYSA-N cobalt(ii) oxide Chemical compound [Co]=O IVMYJDGYRUAWML-UHFFFAOYSA-N 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 208000004042 dental fluorosis Diseases 0.000 description 1
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000003560 epithelium corneal Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000006266 hibernation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 231100001228 moderately toxic Toxicity 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 238000002962 plaque-reduction assay Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/06—Cobalt compounds
- C07F15/065—Cobalt compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (22)
- 1.適当な基剤及び抗ウイルス的に有効な量の化合物からなり、該化合物が下記 の構造: ▲数式、化学式、表等があります▼ [式中、R1及びR1′は同じか又は異なっており、それぞれはアルキル基、フ ェニル基又はフェニル基の置換誘導体であり、R2及びR2′は同じか又は異な っており、それぞれは、水素、非分岐のアルキル基、ハロゲン化物又は構造式▲ 数式、化学式、表等があります▼(但し、Rは水素、アルコキシド基、アルキル 基、又はOHである)を有する基であり、R3及びR3′は同じか又は異なって おり、それぞれは水素又はアルキル基であり、 X及びX′は同じか又は異なっており、それぞれは弱い乃至中間の配位子場強度 を有する水溶性基であり、そして、 Q−は可溶性の、医薬的に受容し得る陰イオンである]を有する抗ウィルス性組 成物。
- 2.R1及びR1′が同じであり、それぞれはC1〜C5のアルキル基、フェニ ル基又はフェニル基の置換誘導体(但し、各置換基は、ハロゲン化物、アルキル 基又は構造式▲数式、化学式、表等があります▼(但し、Rは水素、アルコキシ ド基、アルキル基又はOHである)を有する基であり、R2及びR2′が同じで あり、それぞれはC1〜C3のアルキル基、ハロゲン化物、水素又は構造式▲数 式、化学式、表等があります▼(但し、RはH、CH3又はOHである)を有す る基であり、R3及びR3′が同じであり、それぞれは、C1〜C3のアルキル 基であり、X及びX′が同じであり、それぞれはNH3であり、Q−はBr−又 はCl−である、請求の範囲第1項に記載の抗ウィルス性組成物。
- 3.化合物が、構造式: ▲数式、化学式、表等があります▼ ▲数式、化学式、表等があります▼ ▲数式、化学式、表等があります▼ ▲数式、化学式、表等があります▼ ▲数式、化学式、表等があります▼ ▲数式、化学式、表等があります▼ (式中、Phはフェニル基である) を有する請求の範囲第2項に記載の抗ウィルス性組成物。
- 4.医薬的に受容できる基剤及び抗ウィルス的に有効な量の錯体からなり、錯体 が、同じか異なっていてよい4個の供与体原子Aにより定められる八面体底面及 び同じか異なっていてよい2個の軸配位子供与体原子Bを有するCo(III) 錯体からなり、該供与体原子がCN−と同じか又はこれより小さい配位子場強度 を有し、該錯体がO2−と反応してCo(III)錯体−O2付加物を形成する か、又はO2−を酸化して二酸素及びCo(II)錯体を作る抗ウィルス性組成 物。
- 5.錯体が、供与体原子を介してCo(III)に結合し、八面体底面に平面性 を与える四座配位子Lを有する、請求の範囲第4項に記載の組成物。
- 6.四座配位子L及び結合したCo(III)が6,5,6環系からなり、該6 ,5,6環系の該6員環が不飽和である、請求の範囲第5項に記載の組成物。
- 7.式[CoL(B)2]n(式中、Bは、I−、Br−、Cl−、F−、OH −、C2O42−、H2O、及びNH3からなる群から選択され、nは−1、0 又は+1である)を有する請求の範囲第6項に記載の組成物。
- 8.ウィルスにより起こされる疾患を有する被検体を、医薬的に受容できる基剤 及び抗ウィルス的に有効な量で被検体に投薬される化合物を含む組成物で治療す る方法に於いて、該組成物が請求の範囲第1項に記載の組成物であることからな る改良。
- 9.ウィルスにより起こされる疾患を有する被検体を、医薬的に受容できる基剤 及び抗ウィルス的に有効な量で被検体に投薬される化合物を含む組成物で治療す る方法に於いて、該組成物が請求の範囲第2項に記載の組成物であることからな る改良。
- 10.ウィルスにより起こされる疾患を有する被検体を、医薬的に受容できる基 剤及び抗ウィルス的に有効な量で被検体に投薬される化合物を含む組成物で治療 する方法に於いて、該組成物が請求の範囲第3項に記載の組成物であることから なる改良。
- 11.ウィルスにより起こされる疾患を有する被検体を、医薬的に受容できる基 剤及び抗ウィルス的に有効な量で被検体に投薬される化合物を含む組成物で治療 する方法に於いて、該組成物が請求の範囲第4項に記載の組成物であることから なる改良。
- 12.ウィルスにより起こされる疾患を有する被検体を、医薬的に受容できる基 剤及び抗ウィルス的に有効な量で被検体に投薬される化合物を含む組成物で治療 する方法に於いて、該組成物が請求の範囲第5項に記載の組成物であることから なる改良。
- 13.ウィルスにより起こされる疾患を有する被検体を、医薬的に受容できる基 剤及び抗ウィルス的に有効な量で被検体に投薬される化合物を含む組成物で治療 する方法に於いて、該組成物が請求の範囲第6項に記載の組成物であることから なる改良。
- 14.ウィルスにより起こされる疾患を有する被検体を、医薬的に受容できる基 剤及び抗ウィルス的に有効な量で被検体に投薬される化合物を含む組成物で治療 する方法に於いて、該組成物が請求の範囲第7項に記載の組成物であることから なる改良。
- 15.該ウィルスがヘルペスウィルス及びアデノウィルスからなる群から選択さ れる、請求の範囲第1項、第2項又は第3項に記載の組成物。
- 16.該ウィルスがヘルペスウィルス及びアデノウィルスからなる群から選択さ れる、請求の範囲第4項、第5項、第6項又は第7項に記載の組成物。
- 17.該ウィルスがHSV−1、HSV−2、HCMV及びVZVからなる群が ら選択される請求の範囲第15項に記載の組成物。
- 18.該ウィルスがHSV−1、HSV−2、HCMV及びVZVからなる群か ら選択される請求の範囲第16項に記載の組成物。
- 19.該ウィルスがヘルペスウィルス及びアデノウィルスからなる群から選択さ れる、請求の範囲第8項乃至第14項の何れか一項に記載の方法。
- 20.該ウィルスがHSV−1、HSV−2、HCMV及びVZVからなる群か ら選択される請求の範囲第19項に記載の方法。
- 21.該ウィルスが現存する認可された抗ウィルス剤に耐性である、請求の範囲 第1項乃至第7項の何れか一項に記載の組成物。
- 22.該ウィルスが現存する認可された抗ウィルス剤に耐性である、請求の範囲 第8項乃至第14項の何れか一項に記載の組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/502,294 US5106841A (en) | 1986-05-13 | 1990-03-30 | Antiviral compositions and method for their use |
US502,294 | 1990-03-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH05507065A true JPH05507065A (ja) | 1993-10-14 |
JP3179096B2 JP3179096B2 (ja) | 2001-06-25 |
Family
ID=23997182
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50761791A Expired - Lifetime JP3179096B2 (ja) | 1990-03-30 | 1991-03-28 | 抗ウイルス性組成物及びその使用方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US5106841A (ja) |
EP (1) | EP0522084B1 (ja) |
JP (1) | JP3179096B2 (ja) |
AT (1) | ATE175115T1 (ja) |
AU (1) | AU656521B2 (ja) |
CA (1) | CA2079482C (ja) |
DE (1) | DE69130705T2 (ja) |
IL (1) | IL97729A (ja) |
WO (1) | WO1991015212A1 (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5756491A (en) * | 1986-05-13 | 1998-05-26 | Chai-Tech Corporation | Antiviral cobalt-organic compounds |
US5258403A (en) * | 1986-05-13 | 1993-11-02 | Chai-Tech Corporation | Metallo-organic salt compounds and pharmaceutical uses thereof |
US5696109A (en) * | 1992-12-07 | 1997-12-09 | Eukarion, Inc. | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease |
US5403834A (en) | 1992-12-07 | 1995-04-04 | Eukarion, Inc. | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease |
US5834509A (en) * | 1992-12-07 | 1998-11-10 | Eukarion, Inc. | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease |
US7582786B2 (en) * | 1992-12-07 | 2009-09-01 | Eukarion Inc. | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease |
AU5871494A (en) * | 1992-12-15 | 1994-07-04 | Redox Pharmaceutical Corporation | Antiviral compositions and method for their use |
US6008190A (en) * | 1994-12-15 | 1999-12-28 | California Institute Of Technology | Cobalt Schiff base compounds |
IL124844A0 (en) * | 1995-12-12 | 1999-01-26 | California Inst Of Techn | Cobalt schiff base compounds |
US7732129B1 (en) * | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
DE69737107T2 (de) * | 1996-11-20 | 2007-07-12 | Introgen Therapeutics Inc., Austin | Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren |
WO1999003877A1 (en) * | 1997-07-16 | 1999-01-28 | California Institute Of Technology | Methods of unfolding proteins using metal complexes |
DE69927023T2 (de) * | 1998-06-11 | 2006-06-08 | Redox Pharmaceutical Corp. | Verfahren zur prophylaxe von hiv und hpv |
US6589948B1 (en) | 2000-11-28 | 2003-07-08 | Eukarion, Inc. | Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases |
WO2007013868A2 (en) | 2004-06-30 | 2007-02-01 | Redox Pharmaceutical Corporation Audubon Biomedical Science And Technology Park | Topical antiviral therapeutic and prophylactic treatment of adenoviruses and their associated diseases |
AU2005305347A1 (en) * | 2004-11-03 | 2006-05-18 | Introgen Therapeutics Inc. | Method of producing and purifying of adenoviral vectors |
WO2010111257A2 (en) * | 2009-03-23 | 2010-09-30 | Northwestern University | Targeted schiff base complexes |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3420865A (en) * | 1966-05-12 | 1969-01-07 | Colgate Palmolive Co | Novel carbocyclic ferrocenes |
DE2527158A1 (de) * | 1975-06-18 | 1976-12-23 | Herz Eberhard | Arzneimittel zur behandlung von infektionskrankheiten und von nicht nachweisbar durch mikroorganismen ausgeloeste entzuendungen in der human- und veterinaermedizin |
CA1218600A (en) * | 1982-12-06 | 1987-03-03 | Gerald L. Maurer | Methods and compositions for treating inflammation or arthritis |
US5049557A (en) * | 1986-05-13 | 1991-09-17 | Chai-Tech Corporation | Metallo-organic salt compounds and pharmaceutical uses thereof |
US4866053A (en) * | 1986-05-13 | 1989-09-12 | Chai-Tech Corporation | Method of treating a burn employing a metallo-organic cobalt compound |
-
1990
- 1990-03-30 US US07/502,294 patent/US5106841A/en not_active Expired - Lifetime
-
1991
- 1991-03-28 EP EP91908127A patent/EP0522084B1/en not_active Expired - Lifetime
- 1991-03-28 AU AU76765/91A patent/AU656521B2/en not_active Expired
- 1991-03-28 AT AT91908127T patent/ATE175115T1/de not_active IP Right Cessation
- 1991-03-28 WO PCT/US1991/002146 patent/WO1991015212A1/en active IP Right Grant
- 1991-03-28 DE DE69130705T patent/DE69130705T2/de not_active Expired - Fee Related
- 1991-03-28 JP JP50761791A patent/JP3179096B2/ja not_active Expired - Lifetime
- 1991-03-28 CA CA002079482A patent/CA2079482C/en not_active Expired - Lifetime
- 1991-03-29 IL IL9772991A patent/IL97729A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE69130705T2 (de) | 1999-06-10 |
EP0522084A4 (en) | 1993-03-24 |
JP3179096B2 (ja) | 2001-06-25 |
WO1991015212A1 (en) | 1991-10-17 |
CA2079482C (en) | 2004-07-20 |
IL97729A (en) | 1996-01-31 |
IL97729A0 (en) | 1992-06-21 |
CA2079482A1 (en) | 1991-10-01 |
EP0522084B1 (en) | 1998-12-30 |
ATE175115T1 (de) | 1999-01-15 |
DE69130705D1 (de) | 1999-02-11 |
AU7676591A (en) | 1991-10-30 |
AU656521B2 (en) | 1995-02-09 |
EP0522084A1 (en) | 1993-01-13 |
US5106841A (en) | 1992-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH05507065A (ja) | 抗ウイルス性組成物及びその使用方法 | |
US5846964A (en) | Hepatitis C virus proliferation inhibitor | |
WO1999001103A2 (fr) | Derives de peptides, sels de ces derives acceptables sur le plan pharmaceutique, procede de production de ces derives, utilisation de ces derniers et composition pharmaceutique | |
GB2221390A (en) | Antihyperlipidemic composition comprising niacin and guar gum. | |
JPS62500871A (ja) | 薬理活性を有するジペプチド化合物及びそれを含む組成物 | |
Price et al. | Ointment‐based mechlorethamine treatment for mycosis fungoides | |
JPH06507382A (ja) | 鎌状赤血球症の治療における分子矯正法 | |
JPH0296524A (ja) | 抗癌活性を有する治療薬組成物と癌の治療方法 | |
US4898882A (en) | Resistance imparting agent for cold syndrome of low pulmonary function patients | |
JPH0637388B2 (ja) | 水性液剤 | |
JPH04500670A (ja) | ウイルス感染の治療用方法及び組成物 | |
US5210096A (en) | Antiviral compositions and method for their use | |
US4080442A (en) | Disaccharide derivatives used in the treatment of hepatic diseases | |
US4271191A (en) | Method of treating hyperuricemia and gout | |
JPH11505503A (ja) | 有機塩基カチオンとの2−〔(2,6−ジクロロフェニル)アミン〕フェニルアセトキシ酢酸の新規の塩類 | |
JPS5938207B2 (ja) | 腎疾患治療剤 | |
US3322627A (en) | Method of treating herpes simplex infections with 5-methylamino-2'-deoxyuridine, and compositions therefor | |
CN112266396B (zh) | 一种基于生物正交化学的整合型前药、制备方法及其医药用途 | |
WO2021229832A1 (ja) | ベネトクラクスの水溶性高分子誘導体 | |
Molthan et al. | Clinical use of potassium para-aminosalicylate (KPAS) | |
EP1075186A1 (en) | Method of hsv prophylaxis | |
Bunker Jr | Recent Methods in the Treatment of General Paralysis: A Brief Survey | |
JPH0477428A (ja) | エイズウィルス増殖抑制剤 | |
Turner et al. | The Drugs Handbook 1985–86 | |
JPH049329A (ja) | アレルギー性疾患治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090413 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100413 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110413 Year of fee payment: 10 |
|
EXPY | Cancellation because of completion of term |